ALC Stock Forecast & Price Target

Alcon is well-positioned for long-term growth as it has a dominant presence in both the contact lens and surgical segments, with a strong portfolio of innovative products and a substantial installed base of surgical equipment. The company's recent spin-off from Novartis and its continued focus on product innovation and margin expansion make it an attractive investment opportunity. Further, the company's recent authorization for a $1.5 billion stock repurchase program indicates confidence in its future growth potential and shareholder value creation.

Alcon is facing multiple challenges in the visioncare and surgical segments, including increasing competition from other companies in the contact lens and surgical equipment markets, as well as a slowdown in growth for its intraocular lenses. The discontinuation of its PowerVision accommodating IOL program also raises concerns about its ability to innovate and stay ahead of competitors. Additionally, the ongoing tariff war and expected reinvestment of refunds will put pressure on the company's profitability and earnings growth. These factors, combined with the relatively slow expected growth in the global eye care market, paint a negative outlook for Alcon's stock.